南方地区呼吸道合胞病毒持续流行，呼吸科专家建议将预防关口前移

Core Viewpoint - The Respiratory Syncytial Virus (RSV) is the leading pathogen detected in hospitalized severe acute respiratory infection cases in China, indicating a persistent epidemic status and necessitating enhanced preventive measures [1][2]. Group 1: RSV Prevalence and Impact - RSV has consistently ranked among the top three pathogens in hospitalized severe acute respiratory infection cases from the 4th to the 27th week of 2025, maintaining a detection rate of around 10% [1][2]. - The virus poses a significant threat to infants, particularly those under one year old, as it is the primary cause of lower respiratory infections leading to hospitalization in this age group [1][2]. Group 2: Preventive Measures and Recommendations - Public health measures, including health education and immunization, should be integrated into medical services to reduce the risk of severe cases in infants [1]. - High-risk groups, such as premature infants and those with congenital conditions, are advised to receive the monoclonal antibody Nirsevimab, which is the first preventive measure for all infants against RSV [2]. Group 3: Monitoring and Data Utilization - Continuous monitoring of RSV through weekly reports is essential for understanding its prevalence and guiding preventive strategies [2]. - The protective effect of the monoclonal antibody lasts approximately 5-6 months, aligning with the RSV epidemic season, thus facilitating a connection between prevention and treatment [2].